Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study
Articolo
Data di Pubblicazione:
2020
Abstract:
Several studies have suggested a survival benefit of neoadjuvant therapy (NAT) for pancreatic ductal adenocarcinoma (PDAC) in the pancreatic head. Data concerning NAT for PDAC located in pancreatic body or tail are lacking.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Lof, Sanne; Korrel, Maarten; van Hilst, Jony; Alseidi, Adnan; Balzano, Gianpaolo; Boggi, Ugo; Butturini, Giovanni; Casadei, Riccardo; Dokmak, Safi; Edwin, Bjørn; Falconi, Massimo; Keck, Tobias; Malleo, Giuseppe; de Pastena, Matteo; Tomazic, Ales; Wilmink, Hanneke; Zerbi, Alessandro; Besselink, Marc G; Abu Hilal, Mohammed; Bonds, M.; Capretti, G.; Fiorentini, G.; Giardino, A.; Lombardo, C.; Ricci, C.
Link alla scheda completa:
Pubblicato in: